Oxford Nanopore Technologies and bioMérieux have announced the launch of AmPORE-TB, a research use only (RUO) solution aimed at rapidly detecting mutations associated with antimicrobial resistance in the Mycobacterium tuberculosis complex.
Leveraging Oxford Nanopore's nanopore sequencing technology, AmPORE-TB can analyze 24 genes linked to tuberculosis resistance and deliver comprehensive results in less than a day, using a GridION benchtop device and integrated automated analysis software. Recognized by the World Health Organization as one of the three targeted methods meeting its performance criteria for detecting resistance mutations, this solution addresses a major public health challenge: multidrug-resistant tuberculosis affects approximately 400,000 people each year globally. Manufactured by Oxford Nanopore and distributed by bioMérieux, AmPORE-TB will be deployed primarily in low and middle-income countries, where 99% of new cases are concentrated.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorDiagnostic et services de laboratoire›Diagnostic / labos d'analyse
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 1 965 millions d'euros
Quarterly revenue: 1 965 millions d'euros
Revenue growth: -3,9 %
EBITDA: 440,3 millions d'euros
EBITDA margin: 22,4 %
Net income: 226,1 millions d'euros
Free cash flow: 299 millions d'euros
-235,9 millions d'euros
Guidance from the release
confirme ses perspectives pour 2026 : croissance organique du chiffre d'affaires comprise entre +3% et +5%, CEBIT croissance comprise entre 0% et +10%
Risks mentioned
Épidémiologie respiratoire plus faible : recul organique de 17 % des panels respiratoires BIOFIRE®
Effet de change défavorable de 35 M€ sur le ROCC du premier semestre 2026
Environnement géopolitique et macroéconomique dégradé depuis 2024
Opportunities identified
Croissance organique de 6 % des quatre moteurs de croissance du plan GO•28
Dépôt auprès de la FDA du panel SPOTFIRE® Vaginitis
Obtention du marquage CE du premier test SPINCHIP®
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
